Research on Immune Rechallenge in the Treatment of Non-Small Cell Lung Cancer
OBJECTIVE To summarize the research progress and beneficiary population of immune re challenge in the treatment of non-small cell lung cancer(NSCLC),and provide reference for the treatment of NSCLC in clinical practice.METHODS Using key-words such as"non-small cell lung cancer","immune checkpoint inhibitor","rechallenge",etc.,a combination of topic words and free words was used to search relevant literature from PubMed、Cochrane Library、embase、self-built databases such as China National Knowledge Infrastructure until February 1,2024.RESULTS A total of 526 relevant literature were retrieved,with over 40 valid arti-cles.Among them,there are 6 systematic reviews/Meta analyses on NSCLC rechallenge,5 clinical studies,and most of the rest are retro-spective real-world studies.CONCLUSION The effectiveness and controllable irAEs of immune rechallenge therapy for NSCLC were analyzed,and it was preliminarily believed that patients with high programmed cell death ligand 1(PD-L1)expression(TPS ≥ 50％),good performance status(PS)score in the Eastern Cooperative Oncology Group(ECOG)in the United States(ECOG-PS＜1)and longer initial immunotherapy time were more likely to benefit from ICIs rechallenge.
NETL
NSTL
万方数据
